Magnesium Sulphate for Preterm Birth (MASP Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

December 16, 2011

Primary Completion Date

August 12, 2019

Study Completion Date

August 12, 2019

Conditions
Cerebral Palsy
Interventions
DRUG

Magnesium sulphate

Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.

Trial Locations (14)

2100

Obstetrisk Klinik, Copenhagen

2650

Hanne Trap Wolf, Hvidovre

3400

Gynækologisk-Obstetrisk Afdeling, Hillerød

4300

Gynækologisk Obstetrisk afdeling, Holbæk

4700

Gynækologisk-obstetrisk afdeling, Næstved

5000

Gynækologisk afdeling D, Odense

6000

Gynækologisk-obstetrisk afd., Kolding

6700

Gynækologisk obstetrisk Afdeling, Esbjerg

8200

Gynækologisk-obstetrisk afdeling Y, Aarhus

8600

Gynækologisk-obstetrisk afd., Silkeborg

8800

Kvindeafdeling Y, Viborg

8930

Gynækologisk obstetrisk afdeling, Randers

9100

Gynækologisk-Obstetrisk Afdeling, Aalborg

Unknown

Gynækologisk Obstetrisk afdeling, Herlev

All Listed Sponsors
lead

Hvidovre University Hospital

OTHER

NCT01492608 - Magnesium Sulphate for Preterm Birth (MASP Study) | Biotech Hunter | Biotech Hunter